Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

Novan, Inc. today announced that the first patient has been dosed in the Company’s Phase 1b clinical trial to evaluate topical nitric oxide product candidate SB414 cream for the treatment of mild-to-moderate atopic dermatitis. Novan is developing SB414 as a nitric oxide-releasing topical cream product candidate for the treatment of inflammatory skin diseases.

Read the full press releaseCompany website